Predict your next investment

Corporate Venture
nvfund.com

See what CB Insights has to offer

Investments

329

Portfolio Exits

94

Partners & Customers

1

About Novartis Venture Funds

Novartis Venture Funds primarily focuses on the development of novel therapeutics and platforms. NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. Novartis Venture Funds invests in North America, Europe, Israel and Asia/Pacific and manage over USD 1 billion in committed capital and more than 40 portfolio companies. NVF makes equity investments in life sciences companies across Biotechnology/Biopharma, Medical Devices and Diagnostics. NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically leading or co-leading an investment and playing an active role on company boards.

Novartis Venture Funds Headquarter Location

Basel, CH-4002,

Switzerland

+41 61 324 32 67

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novartis Venture Funds

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novartis Venture Funds in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Novartis Venture Funds

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Novartis Venture Funds in 2 CB Insights research briefs, most recently on Apr 6, 2021.

Latest Novartis Venture Funds News

Advanced Animal Diagnostics Raises $11 Million in Equity Financing

Sep 23, 2020

Investment is single largest in mastitis research and development March 15, 2011 03:10 PM Eastern Daylight Time DURHAM, N.C.--( BUSINESS WIRE )-- Advanced Animal Diagnostics (AAD), a developer of technologies for the rapid diagnosis of farm animal diseases, announced today that it has closed an $11 million Series B round of equity financing. This investment in AAD represents the largest single investment in research and development to diagnose mastitis, the costliest disease for dairy producers worldwide. The financing was led by Intersouth Partners and included Novartis Venture Funds as well as other private investors. AAD is an innovative research and development company dedicated to bringing highly accurate, rapid animal diagnostic tests to the farm. The company’s first on-farm product will focus on improving milk production and quality by controlling mastitis, an infection of the milk-producing gland. Future products will monitor disease states, reproductive, nutritional and overall health status of production animals. The QuickSmear™ rapid differential slide for researchers was the first product commercialized by AAD in 2009. “With this investment, AAD will be able to bring to market a new generation of diagnostics technologies that will revolutionize the way farmers approach animal health, allowing them to detect and diagnose diseases in their animals more quickly and efficiently than ever before,” said Joy Parr Drach, president and CEO of AAD. “We appreciate that our investors recognize the opportunity of investments in agriculture. By bringing our innovative technologies to market, they are supporting the efforts of AAD and agriculture to deliver a safe, affordable and abundant supply of protein.” The company expects this financing to support hiring for key positions, production and manufacturing, and on-farm economic trials of its first product line. The firm is currently seeking cooperators for those on-farm trials. “Food producers are under increasing pressure. The value in AAD’s strong platform of technologies can help them improve animal health and profitability,” said Jimmy Rosen, partner at Intersouth Partners. “We’re excited to support this company and its technology.” Dr. Simon Wheeler, managing director at Novartis Venture Fund, added, “Novartis Venture Fund is confident that with its new technology, AAD will bring significant benefits to the dairy industry and enhance food production worldwide. The investment meets the aim of our fund to provide innovative patient benefit and supports Novartis’s mission to save, prolong and improve animal lives.” AAD technology represents a significant advance for control of mastitis because it allows early identification of infected quarters, or glands, immediately after calving, when the highest incidence of mastitis occurs. With AAD’s highly accurate, rapid on-farm test that works on colostrum, infected cows can be treated immediately and clear the withdrawal period before they’re turned into the milking herd. Early treatment ensures that cows start the lactation cycle healthy, minimizes long-term gland damage that reduces milk production and eliminates the high cost of discarded milk and treatment during lactation. AAD was founded in 2001 and started with a USDA Small Business Innovation Research (SBIR) grant. It received funding from the North Carolina Biotechnology Center including a Collaborative Funding Grant for research at North Carolina State University’s College of Veterinary Medicine. The company previously raised a $1.1 million Series A round of funding from private investors. About Advanced Animal Diagnostics Advanced Animal Diagnostics (AAD) is an innovative company designed to enhance the profitability of livestock production and ensure a safe, abundant supply of animal protein by developing highly accurate, rapid diagnostics to detect and manage disease states, reproductive, nutritional and overall health status of production animals. The firm’s first product is a rapid, on-farm diagnostic test for earlier, more accurate detection of mastitis in dairy cows. For more information about Advanced Animal Diagnostics, please visit www.aadiagnostics.com . About Intersouth Partners Intersouth Partners is one of the most active and experienced early-stage venture funds in the country, having invested in more than 100 private companies over the last two decades. Founded in 1985, Intersouth Partners manages more than $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast. Based in Durham, North Carolina, Intersouth Partners seeks a broad range of seed and early-stage investment opportunities throughout the Southeast, focusing on the technology and life sciences sectors. For more information, please visit www.intersouth.com or follow the firm at @intersouth . About Novartis Venture Funds Established in 1996, the Novartis Venture Fund currently manages over $650 million in committed capital and is invested globally in more than 60 private life sciences companies across therapeutics, vaccines, devices and diagnostics. As a financially driven corporate life science investor, the Novartis Venture Fund invests in those companies which have the potential to lead the next innovation wave in new areas that will be critical to patient care. The Novartis Venture Fund team of nine investment professionals located in Basel, Switzerland, and Cambridge, Massachusetts, brings together extensive expertise in drug development, medical devices and venture capital. www.venturefund.novartis.com Contacts

Novartis Venture Funds Investments

329 Investments

Novartis Venture Funds has made 329 investments. Their latest investment was in Epsilogen as part of their Series B on March 3, 2022.

CBI Logo

Novartis Venture Funds Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/2/2022

Series B

Epsilogen

$41.2M

Yes

10

2/16/2022

Series A

SpliceBio

$56.81M

Yes

4

1/20/2022

Series B

ImmPACT Bio

$111M

No

15

12/16/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/25/2021

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/2/2022

2/16/2022

1/20/2022

12/16/2021

11/25/2021

Round

Series B

Series A

Series B

Series B

Seed VC - II

Company

Epsilogen

SpliceBio

ImmPACT Bio

Subscribe to see more

Subscribe to see more

Amount

$41.2M

$56.81M

$111M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

4

15

10

10

Novartis Venture Funds Portfolio Exits

94 Portfolio Exits

Novartis Venture Funds has 94 portfolio exits. Their latest portfolio exit was Forendo Pharma on November 11, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/11/2021

Acquired

$99M

10

10/22/2021

Acquired

$99M

25

9/3/2021

Reverse Merger

4

7/27/2021

Acquired

Subscribe to see more

Subscribe to see more

10

7/23/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/11/2021

10/22/2021

9/3/2021

7/27/2021

7/23/2021

Exit

Acquired

Acquired

Reverse Merger

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

10

25

4

10

10

Novartis Venture Funds Partners & Customers

1 Partners and customers

Novartis Venture Funds has 1 strategic partners and customers. Novartis Venture Funds recently partnered with Heptares Therapeutics on .

Date

Type

Business Partner

Country

News Snippet

Sources

Licensor

United Kingdom

Welwyn Garden City, UK. MVM Partners LLP : News - Heptares Therapeutics Announces Agreement with Novartis Option Fund

Heptares Therapeutics Limited Ltd , the drug discovery company focused on G-protein-coupled receptor targets , announced today that it has entered into an option agreement with the Novartis under which Heptares Therapeutics Limited will apply its proprietary StaR ™ technology to generate novel drug leads against a nominated , unspecified GPCR target of interest to Novartis .

1

Date

Type

Licensor

Business Partner

Country

United Kingdom

News Snippet

Welwyn Garden City, UK. MVM Partners LLP : News - Heptares Therapeutics Announces Agreement with Novartis Option Fund

Heptares Therapeutics Limited Ltd , the drug discovery company focused on G-protein-coupled receptor targets , announced today that it has entered into an option agreement with the Novartis under which Heptares Therapeutics Limited will apply its proprietary StaR ™ technology to generate novel drug leads against a nominated , unspecified GPCR target of interest to Novartis .

Sources

1

Novartis Venture Funds Team

6 Team Members

Novartis Venture Funds has 6 team members, including current Managing Director, Laura Brass.

Name

Work History

Title

Status

Laura Brass

Managing Director

Current

Florent Gros

Managing Director

Current

Florian Muellershausen

Managing Director

Current

Michal Silverberg

Managing Director

Current

Markus Goebel

Managing Director

Former

Name

Laura Brass

Florent Gros

Florian Muellershausen

Michal Silverberg

Markus Goebel

Work History

Title

Managing Director

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.